SORA

Advancing, promoting and sharing knowledge of health through excellence in teaching, clinical practice and research into the prevention and treatment of illness

Sensorimotor adaptation as a behavioural biomarker of early spinocerebellar ataxia type 6.

Panouillères, MTN; Joundi, RA; Benitez-Riveiro, S; Cheeran, B; Butler, CR; Németh, AH; Miall, RC; Jenkinson, N (2017) Sensorimotor adaptation as a behavioural biomarker of early spinocerebellar ataxia type 6. Sci Rep, 7 (1). p. 2366. ISSN 2045-2322 https://doi.org/10.1038/s41598-017-02469-7
SGUL Authors: Cheeran, Binith

[img]
Preview
PDF Published Version
Available under License Creative Commons Attribution.

Download (1MB) | Preview

Abstract

Early detection of the behavioural deficits of neurodegenerative diseases may help to describe the pathogenesis of such diseases and establish important biomarkers of disease progression. The aim of this study was to identify how sensorimotor adaptation of the upper limb, a cerebellar-dependent process restoring movement accuracy after introduction of a perturbation, is affected at the pre-clinical and clinical stages of spinocerebellar ataxia type 6 (SCA6), an inherited neurodegenerative disease. We demonstrate that initial adaptation to the perturbation was significantly impaired in the eighteen individuals with clinical motor symptoms but mostly preserved in the five pre-clinical individuals. Moreover, the amount of error reduction correlated with the clinical symptoms, with the most symptomatic patients adapting the least. Finally both pre-clinical and clinical individuals showed significantly reduced de-adaptation performance after the perturbation was removed in comparison to the control participants. Thus, in this large study of motor features in SCA6, we provide novel evidence for the existence of subclinical motor dysfunction at a pre-clinical stage of SCA6. Our findings show that testing sensorimotor de-adaptation could provide a potential predictor of future motor deficits in SCA6.

Item Type: Article
Additional Information: This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/. © The Author(s) 2017
SGUL Research Institute / Research Centre: Academic Structure > Molecular and Clinical Sciences Research Institute (MCS)
Journal or Publication Title: Sci Rep
ISSN: 2045-2322
Language: eng
Dates:
DateEvent
24 May 2017Published
11 April 2017Accepted
Publisher License: Creative Commons: Attribution 4.0
Projects:
Project IDFunderFunder ID
G-1108Parkinson's UKhttp://dx.doi.org/10.13039/501100000304
R/J004588/1Medical Research Councilhttp://dx.doi.org/10.13039/501100000265
MR/K010395/1Medical Research Councilhttp://dx.doi.org/10.13039/501100000265
WT087554Wellcome Trusthttp://dx.doi.org/10.13039/100004440
PubMed ID: 28539669
Go to PubMed abstract
URI: http://sgultest.da.ulcc.ac.uk/id/eprint/109482
Publisher's version: https://doi.org/10.1038/s41598-017-02469-7

Actions (login required)

Edit Item Edit Item